Viridian Therapeutics
VRDN
123 hedge funds and large institutions have $770M invested in Viridian Therapeutics in 2023 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 55 increasing their positions, 36 reducing their positions, and 18 closing their positions.
85% more capital inflows, than outflows
Capital inflows: $152M | Capital outflows: $82.3M
53% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 36
4% less funds holding
Funds holding: 128 → 123 (-5)
13.87% less ownership
Funds ownership: 109.25% → 95.38% (-14%)
22% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 18
89% less call options, than puts
Call options by funds: $133K | Put options by funds: $1.17M
89% less funds holding in top 10
Funds holding in top 10: 9 → 1 (-8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deep Track Capital
Greenwich,
Connecticut
|
+$32.1M |
| 2 |
Paradigm Biocapital Advisors
New York
|
+$24.2M |
| 3 |
Braidwell
Stamford,
Connecticut
|
+$10.1M |
| 4 |
Eversept Partners
New York
|
+$8.46M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$8.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cormorant Asset Management
Boston,
Massachusetts
|
-$20.2M |
| 2 |
Perceptive Advisors
New York
|
-$14.6M |
| 3 |
ABG
Ally Bridge Group
New York
|
-$4.8M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
-$4.25M |
| 5 |
Woodline Partners
San Francisco,
California
|
-$4M |
VRDN Hedge Fund Activity: Q3 2023 in Review
123 of the 6,316 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q3 2023, worth a combined $770M — down 31% from $1.12B a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of VRDN and 14 opened new positions — a net loss of 4 holders — while 36 trimmed existing stakes and 55 added.
The largest buyer was Deep Track Capital, adding an estimated $32.1M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $20.2M sold.
- 123 institutional investors held Viridian Therapeutics (VRDN) as of Q3 2023, down from 128 in Q2 2023.
- Funds reported $770M of Viridian Therapeutics stock for Q3 2023, down 31% quarter-over-quarter.
- 14 funds opened new Viridian Therapeutics positions in Q3 2023 and 18 closed out, a net change of -4 holders.
- The largest Viridian Therapeutics buyer in Q3 2023 was Deep Track Capital, an estimated $32.1M added.
- The largest Viridian Therapeutics seller in Q3 2023 was Cormorant Asset Management, an estimated $20.2M sold.
Based on aggregated 13F filings for Q3 2023.